OR2T34

Across TCGA pan-cancer cohorts, OR2T34 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR2T34 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OR2T34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T34 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, SKCM, and SCLC are the cancer types where OR2T34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.171	0.669	.001	12	view →
SKCM	DFS	Median	II,III,IV	0.341	0.303	.014	8	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
LUSC	DFS	Median	II,III,IV	0.139	0.663	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR2T34–LUAD (OS)

Open the LUAD breakdown →